CA2229892A1 - Preparations liposomes de derives indolocarbazole - Google Patents

Preparations liposomes de derives indolocarbazole

Info

Publication number
CA2229892A1
CA2229892A1 CA002229892A CA2229892A CA2229892A1 CA 2229892 A1 CA2229892 A1 CA 2229892A1 CA 002229892 A CA002229892 A CA 002229892A CA 2229892 A CA2229892 A CA 2229892A CA 2229892 A1 CA2229892 A1 CA 2229892A1
Authority
CA
Canada
Prior art keywords
indolocarbazole derivatives
liposome preparations
liposome
formula
indolocarbazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002229892A
Other languages
English (en)
Other versions
CA2229892C (fr
Inventor
Yasuki Kato
Masahiro Yamauchi
Kunio Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2229892A1 publication Critical patent/CA2229892A1/fr
Application granted granted Critical
Publication of CA2229892C publication Critical patent/CA2229892C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002229892A 1996-06-18 1997-06-12 Preparations liposomes de derives indolocarbazole Expired - Fee Related CA2229892C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP15645996 1996-06-18
JP156459/96 1996-06-18
PCT/JP1997/002033 WO1997048398A1 (fr) 1996-06-18 1997-06-12 Preparations liposomes de derives indolocarbazole

Publications (2)

Publication Number Publication Date
CA2229892A1 true CA2229892A1 (fr) 1997-12-24
CA2229892C CA2229892C (fr) 2003-01-07

Family

ID=15628218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002229892A Expired - Fee Related CA2229892C (fr) 1996-06-18 1997-06-12 Preparations liposomes de derives indolocarbazole

Country Status (10)

Country Link
US (1) US6045822A (fr)
EP (1) EP0850646B1 (fr)
AT (1) ATE381932T1 (fr)
AU (1) AU718856B2 (fr)
CA (1) CA2229892C (fr)
DE (1) DE69738416T2 (fr)
DK (1) DK0850646T3 (fr)
ES (1) ES2296311T3 (fr)
PT (1) PT850646E (fr)
WO (1) WO1997048398A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP1190705A4 (fr) * 1999-06-24 2009-03-18 Kyowa Hakko Kogyo Kk Methode de regulation de la fuite de medicaments encapsules dans des liposomes
WO2002045688A2 (fr) * 2000-12-07 2002-06-13 Universiteit Utrecht Holding B.V. Composition pour le traitement de maladies inflammatoires
US7396852B2 (en) * 2005-11-16 2008-07-08 Xerox Corporation Compound having indolocarbazole moiety and divalent linkage
US20060124921A1 (en) * 2004-12-14 2006-06-15 Xerox Corporation Compound with indolocarbazole moieties and devices containing such compound
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
JP5638204B2 (ja) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 経口投与用リポソーム製剤およびその製造方法
EP2883542B1 (fr) 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Dispersion aqueuse de liposome encapsulant un oxaliplatine stable, et procédé de stabilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2766360B2 (ja) * 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
JP2694701B2 (ja) * 1989-08-24 1997-12-24 日本油脂株式会社 液体膜制癌剤
IL100833A0 (en) * 1991-02-20 1992-09-06 Greenwich Pharma Method for synthesis of ethereally substituted blocked monosaccharides
JPH07278016A (ja) * 1994-04-13 1995-10-24 Pola Chem Ind Inc 抗癌剤リポソーム製剤
EP0711556A1 (fr) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Solutions intraveineuses contenant des dérivés de staurosporine

Also Published As

Publication number Publication date
AU3106697A (en) 1998-01-07
EP0850646B1 (fr) 2007-12-26
EP0850646A4 (fr) 2005-06-22
CA2229892C (fr) 2003-01-07
ES2296311T3 (es) 2008-04-16
ATE381932T1 (de) 2008-01-15
WO1997048398A1 (fr) 1997-12-24
AU718856B2 (en) 2000-04-20
EP0850646A1 (fr) 1998-07-01
US6045822A (en) 2000-04-04
PT850646E (pt) 2008-03-31
DE69738416T2 (de) 2008-12-11
DE69738416D1 (de) 2008-02-07
DK0850646T3 (da) 2008-05-13

Similar Documents

Publication Publication Date Title
CA2207694A1 (fr) Procede pour l'obtention du sildenafil
CA2173703A1 (fr) Compose stabilisant synergique
AU4419193A (en) Synthesis of 1,4,7-triazacyclononane derivatives
CA2165819A1 (fr) Derives de dc-89
AU3744397A (en) Total synthesis of antitumor acylfulvenes
CA2181665A1 (fr) Melange stabilisateur synergiste
CA2129542A1 (fr) Preparation pharmaceutique a base de rhamnolipide
AU3106697A (en) Liposome preparations of indolocarbazole derivatives
AU8758298A (en) Process for the preparation of 2'-fluoro-5-methyl-beta -l-arabinofuranosyluridine
AU8759491A (en) Peptides containing substituted 1,4-diamines as transition-state inserts
WO2000046210A3 (fr) Nouveau procede de preparation d'intermediaires pesticides
EP1026162A4 (fr) Agent anti-rhumatismal
EP1008345A4 (fr) Agents anti-allergiques
HUP9802219A3 (en) Processes for the preparation of n-phosphonomethylglycine from n-phosphonomethyliminodiacetic acid
AU2571995A (en) Novel pyrrolidine-2-thione derivatives as herbicides
AU1512097A (en) Process for the preparation of unsymmetrical 4,6-bis(aryloxy)pyriidine compounds
AU4386693A (en) 3-(9-acridinylamino)-5-hydroxymethylaniline derivatives as anticancer agents
WO1999048851A3 (fr) Procedes de preparation d'intermediaires
AU7496991A (en) Liposome preparation
AU2836895A (en) Fulgimide compound
AU2292395A (en) Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity
AU8852791A (en) Pyridil-pyrimidine derivatives as fungicidal compounds
AU4956193A (en) Stable, highly concentrated formulations of fluorescein derivatives
AU7245198A (en) Process for the preparation of high purity o-substituted hydroxylamine derivatives
AU5318398A (en) Process for the preparation of an oligomeric compound

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed